The global contraceptive drugs market size was estimated to be USD 18.46 billion in 2023 and is expected to reach at USD 42.78 billion by 2034 with a CAGR of 7.94% during the forecast period 2024-2034. Growing concern about the rapid global population growth, rising introduction of over-the-counter drugs, surge in adoption of modern techniques, increasing reimbursement policies, growing preference of modern contraceptive methods over conventional methods, rising introduction of new products, surge in population of women of childbearing age, and increasing efforts of major market players & healthcare agencies to raise awareness regarding contraception methods are some of the key factors boosting the market growth.
Contraception is a method employed to prevent undesired pregnancies, manage the birth rate, and lower the risk of sexually transmitted diseases (STDs). Contraceptive drugs are utilized by a specific group of individuals to avoid pregnancy and STIs, as well as for family planning and birth control. Therefore, increasing efforts of major market players & healthcare agencies to raise awareness regarding contraception methods is predicted to boost the market growth during the forecast period. For instance, in September 2022, Mankind Pharma's standard oral contraceptive product, Unwanted 21, initiated a multilingual campaign in celebration of World Contraception Day.
By product, oral was the highest revenue-grossing segment in the global contraceptive drugs market in 2023 owing to the significant clinical advantages of oral medications compared to other contraceptive methods, the convenience of administering oral pills, increasing availability in pharmacies, public hospitals, & other healthcare facilities, rising adoption of oral drugs across the globe, and surge in product approvals. For instance, in November 2022, The U.S. FDA has granted approval for Lupin's Drospirenone tablets, which are intended for pregnancy prevention. These tablets serve as the generic equivalent of Exeltis USA Inc's Slynd tablets. Additionally, injectable is predicted to grow at fastest CAGR during the forecast period owing to the relatively lower annual cost when compared to drugs & pills and growing awareness regarding the injectable contraceptives.
By distribution channel, retail pharmacy was the highest revenue-grossing segment in the global contraceptive drugs market in 2023 owing to the surge in demand for OTC contraception drugs, rising awareness regarding various contraception methods, increasing preference of consumers toward retail pharmacies for procuring birth control pills, growing favorable regulatory policies, and surge in launch of new drugs. For instance, In July 2022, Mithra Pharmaceuticals, SA, and Mayne Pharma Group Limited have jointly announced the availability of NEXT STELLIS in Australia. This is an oral contraceptive featuring a unique type of estrogen. Additionally, online channels is predicted to grow at fastest CAGR during the forecast period owing to the rising use of over-the-counter remedies, coupled with a variety of online promotions and discounts designed to attract customers, the extensive distribution network & the constant availability of various brands of drugs, including oral pills, injectables, & patches.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising awareness regarding birth control pills, increasing population of women of childbearing age & the fertility rate, and surge in approval of novel drugs by regulatory bodies. For instance, in July 2023, The U.S. FDA has given its approval for Opill (norgestrel) tablets, marking the first non-prescription oral contraceptive designed for daily use. This product is produced by Laboratoire HRA Pharma, which was recently acquired by Perrigo Company plc. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in government initiatives to expand access to contraceptive drugs, growing awareness regarding pills, rising demand for these drugs, increasing emphasis on family planning, surge in number of unintended pregnancies, and growing approvals by regulatory bodies. For instance, in August 2023, Lupin has obtained approval from the U.S. FDA for its Turqoz (Norgestrel and Ethinyl Estradiol Tablets USP), which is a generic counterpart of Wyeth Pharmaceuticals LLC's Lo/Ovral-28 tablets.
Contraception is a method employed to prevent undesired pregnancies, manage the birth rate, and lower the risk of sexually transmitted diseases (STDs). Contraceptive drugs are utilized by a specific group of individuals to avoid pregnancy and STIs, as well as for family planning and birth control. Therefore, increasing efforts of major market players & healthcare agencies to raise awareness regarding contraception methods is predicted to boost the market growth during the forecast period. For instance, in September 2022, Mankind Pharma's standard oral contraceptive product, Unwanted 21, initiated a multilingual campaign in celebration of World Contraception Day.
By product, oral was the highest revenue-grossing segment in the global contraceptive drugs market in 2023 owing to the significant clinical advantages of oral medications compared to other contraceptive methods, the convenience of administering oral pills, increasing availability in pharmacies, public hospitals, & other healthcare facilities, rising adoption of oral drugs across the globe, and surge in product approvals. For instance, in November 2022, The U.S. FDA has granted approval for Lupin's Drospirenone tablets, which are intended for pregnancy prevention. These tablets serve as the generic equivalent of Exeltis USA Inc's Slynd tablets. Additionally, injectable is predicted to grow at fastest CAGR during the forecast period owing to the relatively lower annual cost when compared to drugs & pills and growing awareness regarding the injectable contraceptives.
By distribution channel, retail pharmacy was the highest revenue-grossing segment in the global contraceptive drugs market in 2023 owing to the surge in demand for OTC contraception drugs, rising awareness regarding various contraception methods, increasing preference of consumers toward retail pharmacies for procuring birth control pills, growing favorable regulatory policies, and surge in launch of new drugs. For instance, In July 2022, Mithra Pharmaceuticals, SA, and Mayne Pharma Group Limited have jointly announced the availability of NEXT STELLIS in Australia. This is an oral contraceptive featuring a unique type of estrogen. Additionally, online channels is predicted to grow at fastest CAGR during the forecast period owing to the rising use of over-the-counter remedies, coupled with a variety of online promotions and discounts designed to attract customers, the extensive distribution network & the constant availability of various brands of drugs, including oral pills, injectables, & patches.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising awareness regarding birth control pills, increasing population of women of childbearing age & the fertility rate, and surge in approval of novel drugs by regulatory bodies. For instance, in July 2023, The U.S. FDA has given its approval for Opill (norgestrel) tablets, marking the first non-prescription oral contraceptive designed for daily use. This product is produced by Laboratoire HRA Pharma, which was recently acquired by Perrigo Company plc. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in government initiatives to expand access to contraceptive drugs, growing awareness regarding pills, rising demand for these drugs, increasing emphasis on family planning, surge in number of unintended pregnancies, and growing approvals by regulatory bodies. For instance, in August 2023, Lupin has obtained approval from the U.S. FDA for its Turqoz (Norgestrel and Ethinyl Estradiol Tablets USP), which is a generic counterpart of Wyeth Pharmaceuticals LLC's Lo/Ovral-28 tablets.
Segmentation: Contraceptive Drugs Market Report 2023 - 2034
Contraceptive Drugs Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Patches
- Injectable
- Oral
- Progestin-Only Pills
- Combined Contraceptives
Contraceptive Drugs Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Online Channels
- Hospital Pharmacy
- Retail Pharmacy
- Public Channels & NGOs
- Clinics
- Others
Contraceptive Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Contraceptive Drugs Market: Product Estimates & Trend Analysis
8. Contraceptive Drugs Market: Distribution Channel Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Contraceptive Drugs Market
11. Europe Global Contraceptive Drugs Market
12. Asia Pacific Global Contraceptive Drugs Market
13. Latin America Global Contraceptive Drugs Market
14. MEA Global Contraceptive Drugs Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Pfizer Inc.
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Allergan Plc.
- Lupin Ltd
- Novartis AG
- GlaxoSmithKline Plc
- Johnson & Johnson
- Piramal Healthcare
- Mylan N.V.
- Agile Therapeutics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 18.46 Billion |
| Forecasted Market Value ( USD | $ 42.78 Billion |
| Compound Annual Growth Rate | 7.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
